Immunotherapeutic strategies in antiphospholipid syndrome.

about

Immunotherapeutic strategies in antiphospholipid syndrome.

Item

http://www.wikidata.org/entity/Q38826804

description

2016 nî lūn-bûn

@nan

2016 թվականի օգոստոսի 30-ին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

name

Immunotherapeutic strategies in antiphospholipid syndrome.

@en

type

Item

label

Immunotherapeutic strategies in antiphospholipid syndrome.

@en

prefLabel

Immunotherapeutic strategies in antiphospholipid syndrome.

@en

P1476

Immunotherapeutic strategies in antiphospholipid syndrome.

@en

P2093

A Y Hoi

http://www.w3.org/2001/XMLSchema#string

J Day

http://www.w3.org/2001/XMLSchema#string

L Ross

http://www.w3.org/2001/XMLSchema#string

R R C Buchanan

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H)

Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisone plus low-dose aspirin

A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome

Real world experience with antiphospholipid antibody tests: how stable are results over time?

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

A critical role for murine complement regulator crry in fetomaternal tolerance

A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)

Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria: a 6-year follow-up study.

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.

A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome.

P304

250-256

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IMJ.13245

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27572264

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy